Implantica publishes Interim Report January – September 2026 (Q3)

FDA APPROVAL SECURED AND FIRST U.S. PATIENTS TREATED AT USC

Significant events in the third quarter of 2026

- FDA Premarket Approval (PMA) granted for RefluxStop® on August 20, opening the world's largest medical device market and enabling a U.S. commercial launch
- European sales grew 105% year-on-year in Q3, supported by expanding hospital adoption, including at selected centers such as Evangelisches Krankenhaus Wesel in Germany and Hospital Quirónsalud San José in Madrid
- U.S. launch kicked off at the American Foregut Society Annual Meeting, receiving an exceptional reception from leading surgeons and gastroenterologists, with over 120 symposium attendees and nearly 30 individual meetings
- U.S. organization significantly strengthened with highly experienced new team members, including three Regional Head of Sales Directors, a Surgical Training Lead and two clinical affairs professionals, supporting U.S. commercialization

Significant events after the end of the period

- First RefluxStop® procedures successfully performed in the U.S. in early November by leading anti-reflux surgeon Dr. John Lipham at the University of Southern California (USC), marking a historic commercial milestone
- European Foregut Society meeting held mid-November included a well-attended RefluxStop® symposium, where two comparative studies of RefluxStop® and fundoplication were presented, showing outcomes significantly superior with RefluxStop®
- Training of our U.S. sales team and a handful of U.S. surgeons next in line to start with RefluxStop® completed, with the U.S. surgeon training program ongoing for additional leading U.S. surgeons

Financial summary third quarter 2026

- Net sales increased by 105% to TEUR 748 (365).
- Adjusted gross margin amounted to 94% (93%).
- Operating loss (EBIT) amounted to TEUR 4,511 (4,432).
- Loss after tax amounted to TEUR 3,406 (4,415).
- Basic and diluted loss per Class A share amounted to EUR 0.05 (0.06).
- Cash and short-term investments as at the end of the period of MEUR 38.3.

First nine months

- Net sales increased 51% to TEUR 2,322 (1,543).
- Adjusted gross margin amounted to 94% (94%).
- Operating loss (EBIT) decreased to TEUR 12,569 (13,130).
- Loss after tax amounted to TEUR 11,673 (12,627).
- Basic and diluted loss per Class A share amounted to EUR 0.17 (0.18).

Telephone conference

Implantica will hold a teleconference on 19 November 2026 at 15:00 (CET) with Peter Forsell (CEO), Andreas Öhrnberg (CFO), and Nicole Pehrsson (Chief Corporate Affairs Officer). Please see the dial-in details below to join the conference:

Webcast
If you wish to participate via webcast, please use the following link:
https://implantica.events.inderes.com/q3-report-2026

Dial-in
Dial-in numbers to the teleconference will be received by registering on the link below. After the registration, you will be provided phone numbers and a conference ID to access the conference.

https://events.inderes.com/implantica/q3-report-2026/dial-in

For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)43 505 20 57
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-19 08:00 CET.

About Implantica
Implantica is a medtech company focused on bringing advanced implantable technologies into the body designed to improve patient outcomes and quality of life. The company's lead product, RefluxStop®, is an FDA approved and CE-marked implant for the treatment of gastroesophageal reflux disease (GERD) with the potential to transform the standard of care in anti-reflux surgery, supported by strong long-term clinical outcomes.
In addition to RefluxStop®, Implantica has developed a broad, patent-protected product pipeline partly incorporating two platform technologies: an eHealth platform designed to enable communication with and remote monitoring and control of implants inside the body, and a wireless energizing platform designed to wirelessly power implantable devices through intact skin. These investigational devices are intended to facilitate remote changes to treatment, potentially saving cost for society.
Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

About RefluxStop®
RefluxStop® is a treatment for GERD designed to address the root cause of acid reflux. Conventional anti-reflux surgical procedures typically rely on encircling the esophagus and are often associated with side effects such as swallowing difficulties, inability to belch or

vomit, and gas bloating. RefluxStop is different and aims to restore and maintain the lower esophageal sphincter in its natural anatomical position without encircling or applying pressure on the food passageway. Commercial performance from a multitude of centers supports the clinical study data collected and shows that the RefluxStop® device can successfully treat GERD without wrapping or constricting the esophageal sphincter, thereby avoiding the side effects commonly seen with the other current treatment approaches. Long-term 5-year clinical outcomes on RefluxStop® have been published in peer-reviewed scientific journals and support that a significant portion of the patient population will achieve clinically meaningful results, with minimal risks, when used in accordance with the indications for use.

Indications for Use: RefluxStop® is an implantable sterile medical device intended to treat acid and non-acid reflux in patients diagnosed with gastroesophageal reflux disease (GERD). The device ensures maintenance of a normal physiological situation for the gastroesophageal junction (GEJ) in a defined intra-abdominal position, allowing natural physiological function of the lower esophageal sphincter (LES), thereby reducing or eliminating acid and non-acid reflux. The RefluxStop® Deployment Tool is indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD), defined by abnormal impedance pH and/or pH testing, and indicated for RefluxStop® implantation.